Therapeutic Approach for Preventing Fetal Alcohol Spectrum Disorder (FASD) ID: 2013-028
A novel therapeutic strategy targeting Kir2.1 channels to prevent developmental defects caused by prenatal alcohol exposure.
Photo by starlineart - stock.adobe.com
Technology Overview
This invention from Brigham Young University presents a groundbreaking approach to prevent Fetal Alcohol Spectrum Disorder (FASD) by targeting inwardly rectifying potassium channels, specifically Kir2.1. By utilizing drugs or chemicals that influence these channels during pregnancy, the invention aims to mitigate the developmental defects associated with alcohol exposure, offering a proactive solution to a problem currently lacking effective treatments.
Key Advantages
- First-of-its-kind chemical intervention for preventing FASD
- Targets the biological underpinnings of alcohol-induced developmental defects
- Offers a proactive and potentially more effective solution compared to current preventive measures like counseling
- Backed by Brigham Young University with a manuscript pending publication, highlighting its scientific credibility
Problems Addressed
- Lack of effective treatments for preventing FASD
- Developmental defects in fetuses due to prenatal alcohol exposure
Market Applications
- Pharmaceutical interventions for pregnant women at risk of FASD
- Therapeutic solutions in prenatal care to prevent developmental disorders
- Potential licensing opportunities for drug development companies focused on maternal-fetal health
Additional Information
Technology ID: 2013-028
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 13 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report